March 27, 2006

DexCom Receives FDA Approval For STS™ Continuous Glucose Monitoring System

Novel Technology Designed To Help People With Diabetes Manage Blood Sugar Levels

Dexcom Receives FDA Approval For STS™ Continuous Glucose Monitoring System

San Diego, CA – March 27, 2006 – DexCom, Inc. (NASDAQ: DXCM) today announced that it has received Food and Drug Administration (FDA) approval for its STS Continuous Glucose Monitoring System, a first generation device designed to help people with diabetes more conveniently and effectively manage their blood sugar levels. Widely recognized as one of the leading causes of death and disability in the United States, diabetes is a chronic disease with no known cure that afflicts approximately 20 million people in the U.S., according to the Center for Disease Control (CDC). In the U.S., diabetes is the leading cause of adult blindness, end stage kidney failure and lower limb amputations. People suffering from diabetes are also more significantly at risk for cardiovascular disease and stroke.

"We are very pleased the FDA has approved the DexCom STS Continuous Glucose Monitoring Product and are hopeful this novel technology will improve the quality of life for people living with diabetes," said Andrew P. Rasdal, DexCom President and Chief Executive Officer.

The DexCom STS consists of a tiny wire-like sensor that is inserted by the patient just under the skin. The sensor continuously measures glucose levels which are transmitted wirelessly to the cell phone-like STS Receiver. With the push of a button, the handheld Receiver conveniently provides the patient with real-time glucose measurements and trends, as well as providing alerts to warn of high and low glucose levels. The results of a study on the DexCom STS published in the January 2006 edition of Diabetes Care, a publication of the American Diabetes Association, demonstrated patients could achieve better control of glucose levels when using the information from the DexCom STS.

"We are appreciative of the efforts by the FDA and FCC to help make this technology available to people with diabetes," said Rasdal. "Further, we are especially thankful for the support of the patients, physicians, nurses, and diabetes educators who have participated in our clinical studies supporting this approval."

DexCom management will hold a conference call starting at 4:30 PM (Eastern Time) on Monday, March 27, 2006 to discuss this important development. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom Inc. website www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (800) 811-0667 (US/Canada) or (913) 981-4901 (International) and use the participant code "6796471" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is a technology-focused, independent company pioneering novel, disruptive technology to continuously monitor glucose levels in people with diabetes.

Cautionary Statement Regarding Forward Looking Statements

We have not sold any of our products to date. Successful commercialization of our products is subject to various risks and uncertainties, including possible delays in our development program, the inability of patients to receive reimbursements from third-party payers, a lack of acceptance in the marketplace by physicians and patients, inadequate financial and other resources, and the inability to manufacture products in commercial quantities at an acceptable cost.

FOR MORE INFORMATION:

Investors:
Steve Kemper
Chief Financial Officer
(858) 200-0200

Media:
Citigate Sard Verbinnen

Lesley Bogdanow (212) 687-8080
Paul Kranhold (415) 618-8750



Close window | Back to top

Copyright 2017 DexCom